WOBURN, Mass. , March 05, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the recent publication of three additional DPNCheck clinical studies. DPNCheck is a point-of-care test that provides accurate and cost-effective screening, diagnosis and monitoring of peripheral
WOBURN, Mass. , March 11, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its Quell technology commercial strategy and pipeline. An estimated 100 million US adults have chronic pain. People with chronic pain may also have low quality sleep, anxiety, depression,
WOBURN, Mass. , April 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that, due to the public health impact of the COVID-19 pandemic and in accordance with orders issued by the Governor of the Commonwealth of Massachusetts , the Company’s 2020 Annual Meeting of
WOBURN, Mass. , April 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 first quarter financial results before the opening of the market on Thursday, April 23, 2020 . The Company will host a conference call at 8:00 a.m., Eastern Time on
WOBURN, Mass. , April 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology has been selected for use in a large, NIH -funded, randomized, pragmatic clinical trial of TENS for fibromyalgia. Fibromyalgia is a disorder characterized by widespread
WOBURN, Mass. , April 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2020 . The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic
WOBURN, Mass. , June 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain. This effort includes direct-to-consumer digital marketing as well as informing physicians and other health care providers
WOBURN, Mass. , June 25, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has signed a collaboration agreement with Biomedix to comarket DPNCheck for peripheral neuropathy detection within Medicare Advantage and other value-based care markets.
WOBURN, Mass. , July 09, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expanded distribution in China for DPNCheck, a fast, accurate and quantitative nerve conduction test for evaluation of peripheral neuropathies such as diabetic peripheral neuropathy (DPN).
WOBURN, Mass. , July 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 second quarter financial results before the opening of the market on Thursday, July 23, 2020 . The Company will host a conference call at 8:00 a.m., Eastern Time on July
